Merck & Company (MRK) Buy, Sell or Hold

Home

Daily Stock Opinions and Ratings

Merck & Company (MRK)

152.55

+3.56 (2.39%)

as of Aug 21, 2026, 8:00:00 pm Market Open.

311 watching

Investor Insights

Aug 22, 2026, 12:00 am

This summary was created by AI, based on 25 opinions in the last 12 months.

Merck & Company (MRK) remains a focal point in the pharmaceutical sector, particularly due to its leading cancer treatment drug, Keytruda, which accounts for a significant portion of its revenue but faces a patent expiration in 2028. Experts note that while revenue growth has been modest in the past few years, recent breakthroughs in cancer trials have generated optimism for the company's potential future. There is a general recognition of Merck's strong pipeline of upcoming drugs, which could help offset the revenue decline anticipated from Keytruda going off-patent. Several experts have recommended strict stop-loss strategies to protect investments while pursuing gains, emphasizing a balance of growth potential and valuation concerns. Overall, the sentiment leans towards cautious optimism as analysts grapple with Merck's future amidst challenges and opportunities.

Consensus

positive

Valuation

fair value

Similar

Pfeizer, PFE

PAST TOP PICK

(A Top Pick July 12/04. Down 40%.) Sold out before the big drop.

BUY

Pharmaceuticals are cheaper than he has ever seen them. Cheap. Trading at low multiples.

DON'T BUY

Took a tremendous hit with their withdrawal of Vioxx. Buying it now would be bottom fishing. A lot of issues going on in the pharma sector now. Weak pipeline.

DON'T BUY

Has declined because of a recall of one of their drugs. Will probably have a bounce.

PAST TOP PICK

(A Top Pick Apr 28/04. Down 4%.) Had bought for the wrong reasons. Bought at the top of a cycle as a defensive play. Don't buy.

TOP PICK

Dividend yield is very attractive. You pay very little for the upside.

TOP PICK

Yield is over 3%. Trading around 15 X next year's earnings.

TOP PICK

This late in the cycle, look for stocks that are large, overlooked and underowned. Had a low in 2002 and a higher low at the end of 2003 in a downtrend, still expects to see money going to this group.

WEAK BUY

Have more patent issues than the majority of the big pharmas. Not a lot of catalysts. If you are a real long-term, patient investor, not a bad buy.

BUY

Big pharma stocks should do well in this market. Historically, they do well when rates start to move up.

DON'T BUY

Still under a major downtrend line. Trying to find a base.

TOP PICK

A quiet stock in that not many people are expecting much from them, 7/8% growth this year but you do get a nice 3%+ dividend yield while you wait. Trades at about 15 X earnings. Has a new cholesterol drug coming out this year.

BUY

Has had problems with patent expiry's and drugs in its channel. Gives a 3% dividend yield. Continues to like.

TOP PICK

trading at significantly less than fair value. Bad news on drug development. Dividends at 3.3%

DON'T BUY

Have had tremendous issues. They had to stop production on a couple of drugs that were being tested. Virtually no revenue or earnings coming.

Showing 256 to 270 of 310 entries

Most Recent Experts

Rob Sechan, Managing Partner, New Edge Capital

New Edge Capital

Jenny Harrington, CEO, Gilman Hill Asset Management

Gilman Hill Asset Management

Josh Brown, CEO, Ritholtz Wealth Management

Ritholtz Wealth Management

Amy Raskin, CIO, Chevy Chase Trust

Chevy Chase Trust

Darren Sissons

Campbell Lee & Ross

Wealthica The ultimate 360° Tracker Your financial life in one place, automatically

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

Summer Sale

Merck & Company (MRK)